Armata Pharmaceuticals, Inc.ARMPNYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank36
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P36
Within normal range
vs 5Y Ago
-8.9x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-5.88%
202423.48%
202343.57%
2022-10.19%
20213.95%
20200.66%
201938.79%
2018-24.87%
2017-9.78%
201631.02%